Stay updated on Nivolumab and Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab and Ipilimumab in Melanoma Clinical Trial page
- Check4 days agoChange DetectedA related-topic link for melanoma was added to the study’s resource links.SummaryDifference0.1%

- Check11 days agoChange DetectedThe record now presents details for the completed CheckMate 915 melanoma trial, including its design, eligibility criteria, outcomes, and study locations, instead of an error page.SummaryDifference100%

- Check18 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide NIH banner announces a transition to using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) across NIH content.SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer’s site revision changed from v3.7.0 to v3.7.1. The page still displays a 403 error instead of the study record.SummaryDifference0.2%

Stay in the know with updates to Nivolumab and Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.